News
BGNE
176.50
+1.02%
1.78
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
Seeking Alpha · 2d ago
BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment
TipRanks · 3d ago
BeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy Rating
TipRanks · 4d ago
BeiGene’s Strategic Advancements and Promising Pipeline Drive Buy Rating
TipRanks · 4d ago
BeiGene (BGNE) Gets a Buy from TD Cowen
TipRanks · 4d ago
BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures
Simply Wall St · 4d ago
BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials
TipRanks · 5d ago
Weekly Report: what happened at BGNE last week (1209-1213)?
Weekly Report · 5d ago
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?
Benzinga · 6d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/13 16:10
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
Benzinga · 12/13 07:25
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Barchart · 12/12 18:30
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 12/12 04:38
BeiGene’s Strong Pipeline and Financial Position Make It a Compelling Buy Opportunity
TipRanks · 12/11 14:55
Insider Sale: Director at $BGNE (BGNE) Sells 916,964 Shares
Barchart · 12/11 06:42
BeiGene’s Promising CLL Market Potential: Buy Rating Driven by Strong BTK Degrader Data and Competitive Edge
TipRanks · 12/10 13:05
BEIGENE LTD - ENTERS $400 MILLION FACILITY AGREEMENT WITH CHINA MERCHANTS BANK
Reuters · 12/10 11:03
Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
Benzinga · 12/10 07:06
BeiGene discloses new data in BRUKINSA, promising advancements pipeline at ASH
TipRanks · 12/10 01:35
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Barchart · 12/09 19:30
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.